Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25530844 | 0.82 | GRM2 (0.35) | GRM2DPP4LMNACYP2C19HSD17B10 | |
| SCHEMBL25530377 | 0.82 | GRM2 (0.35) | GRM2DPP4LMNACYP2C19HSD17B10 | |
| SCHEMBL25530380 | 0.82 | GRM2 (0.35) | GRM2DPP4LMNACYP2C19HSD17B10 | |
| SCHEMBL22254698 | 0.80 | GRM2 (0.33) | GRM2DPP4LMNACYP2C19HSD17B10 | |
| SCHEMBL22248565 | 0.79 | CHRM1 (0.40) | DPP4LMNAHSD17B10CHRM1 | |
| SCHEMBL24310950 | 0.79 | MMP1 (0.35) | GRM2AGTR2P2RX7KCNH2CHRM1 | |
| SCHEMBL27617063 | 0.78 | AGTR2 (0.36) | AGTR2P2RX7KCNH2CHRM1 | |
| SCHEMBL15451884 | 0.77 | CYP1A2 (0.45) | AGTR2P2RX7CHRM1 | |
| SCHEMBL4353389 | 0.75 | USP2 (0.44) | HSD17B10 | |
| SCHEMBL191941 | 0.75 | USP2 (0.44) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | GRM2 4612/4885DPP4 130/4885LMNA 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.